Lv1
70 积分 2023-07-24 加入
Non-Invasive Tumor Immune Dysfunction and Exclusion Evaluation and Chemoimmunotherapy Response Prediction in Lung Adenocarcinoma Using Pathomic-Based Approach
2个月前
已完结
Validation of the proposed IASLC residual tumor classification to upgrade extracapsular extension of tumor in nodes from R0 to incomplete resection
1年前
已完结
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
1年前
已完结
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
1年前
已完结
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
1年前
已完结
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
1年前
已完结
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
1年前
已完结
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
1年前
已完结
Tislelizumab plus chemotherapy for patients withEGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
1年前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
1年前
已完结
皖公网安备34019202002308
